Similar articles for PMID: 23006540

Year	Number of Results
1997	1
1998	3
2000	2
2001	1
2002	3
2003	1
2004	4
2005	5
2006	6
2007	7
2008	9
2009	14
2010	12
2011	18
2012	23
2013	18
2014	24
2015	20
2016	21
2017	15
2018	20
2019	14
2020	19
2021	29
2022	21
2023	7
2024	0

1

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.

Gao L, Zhao FL, Li SC. Gao L, et al. Int J Technol Assess Health Care. 2012 Oct;28(4):436-44. doi: 10.1017/S0266462312000608. Epub 2012 Sep 24. Int J Technol Assess Health Care. 2012. PMID: 23006540

2

Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.

Steen Carlsson K, Persson U. Steen Carlsson K, et al. J Med Econ. 2014 Sep;17(9):658-69. doi: 10.3111/13696998.2014.933110. Epub 2014 Jun 26. J Med Econ. 2014. PMID: 24950434 Free article.

3

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Valentine WJ, et al. Clin Ther. 2011 Nov;33(11):1698-712. doi: 10.1016/j.clinthera.2011.09.022. Epub 2011 Oct 21. Clin Ther. 2011. PMID: 22018679

4

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

Lee WC, Conner C, Hammer M. Lee WC, et al. Curr Med Res Opin. 2011 May;27(5):897-906. doi: 10.1185/03007995.2011.559444. Epub 2011 Feb 25. Curr Med Res Opin. 2011. PMID: 21348806 Clinical Trial.

5

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.

Lee WC, Conner C, Hammer M. Lee WC, et al. Clin Ther. 2010 Sep;32(10):1756-67. doi: 10.1016/j.clinthera.2010.08.010. Clin Ther. 2010. PMID: 21194600

6

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

Davies MJ, Chubb BD, Smith IC, Valentine WJ. Davies MJ, et al. Diabet Med. 2012 Mar;29(3):313-20. doi: 10.1111/j.1464-5491.2011.03429.x. Diabet Med. 2012. PMID: 21883438 Free PMC article.

7

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

Lee WC, Samyshkin Y, Langer J, Palmer JL. Lee WC, et al. J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13. J Med Econ. 2012. PMID: 22834986 Free article.

8

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.

Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ. Palmer JL, et al. Adv Ther. 2008 Aug;25(8):752-74. doi: 10.1007/s12325-008-0080-4. Adv Ther. 2008. PMID: 18704282

9

Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.

Gu S, Deng J, Shi L, Mu Y, Dong H. Gu S, et al. J Med Econ. 2015;18(10):808-20. doi: 10.3111/13696998.2015.1049542. Epub 2015 Jul 1. J Med Econ. 2015. PMID: 25950193 Free article.

10

Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.

Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M. Jendle J, et al. J Med Econ. 2012;15 Suppl 2:1-5. doi: 10.3111/13696998.2012.703633. Epub 2012 Aug 1. J Med Econ. 2012. PMID: 22853443 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

283 results

Results by year